Screener
BridgeBio Pharma BBIO Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Cost of license, services, and royalty revenue | $17.6M— | $10.3M— | $4.4M— | $9.1M— | —— | |
| License and services revenue | $5.8M-84.5% | $4.42M-94.5% | $2.88M+1.8% | $8.31M+204% | $37.44M+2,780% | |
| Royalty revenue | $15.43M+850% | $9.5M+4,557% | $5.28M+3,024% | $4.28M— | $1.62M— | |
| Percentage of concentration risk by Geography | ||||||
| APAC | 0.7%-2.9pp | 1.1%-1.2pp | —— | 2.7%-82.3pp | 3.6%-62.5pp | |
| EMEA | 8.1%-23.6pp | 6%-60.1pp | —— | 7.7%-5.5pp | 31.7%+15.0pp |
FAQ
- How does BridgeBio Pharma break its business down?
- BridgeBio Pharma (BBIO) reports revenue by product across 3 parts — Cost of license, services, and royalty revenue, License and services revenue and Royalty revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does BridgeBio Pharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BridgeBio Pharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
